BioCentury
ARTICLE | Product Development

Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair

Focus will be on modest, early-stage deals as the pharma seeks next blockbuster

February 5, 2021 2:30 AM UTC

As Merck’s Robert Davis prepares to take the helm as CEO, his primary challenge will be executing on a pipeline robust enough to carry the pharma over Keytruda’s coming patent cliff. 

Chairman and CEO Ken Frazier will step down on June 30 and hand over the reins to Davis, who is EVP, global services and CFO. Frazier will stay on as executive chairman through a to-be-determined transition period. ...

BCIQ Company Profiles

Merck & Co. Inc.